Benztropine mesylate - Generic Drug Details

What are the generic sources for benztropine mesylate and what is the scope of freedom to operate?

Benztropine mesylate is the generic ingredient in two branded drugs marketed by Fresenius Kabi Usa, Hikma, Hikma Farmaceutica, Luitpold, Navinta Llc, Epic Pharma Llc, Aiping Pharm Inc, Chartwell Rx, Invagen Pharms, Lannett Co Inc, Leading, Nuvo Pharm, Oxford Pharms, Ph Health, Pliva, Quagen, Quantum Pharmics, Usl Pharma, and Merck, and is included in thirty NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for benztropine mesylate. Twenty-one suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for benztropine mesylate

US Patents:	0
Tradenames:	2
Applicants:	19
NDAs:	30
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	21
Raw Ingredient (Bulk) Api Vendors:	124
Clinical Trials:	2
Drug Prices:	Drug price trends for benztropine mesylate
What excipients (inactive ingredients) are in benztropine mesylate?	benztropine mesylate excipients list
DailyMed Link:	benztropine mesylate at DailyMed

See drug prices for benztropine mesylate

See drug sales revenues for benztropine mesylate

Recent Clinical Trials for benztropine mesylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Aarhus	PHASE4
Central Denmark Region	PHASE4
Aarhus University Hospital	PHASE4

See all benztropine mesylate clinical trials

Generic filers with tentative approvals for BENZTROPINE MESYLATE

Applicant	Application No.	Strength	Dosage Form
		1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**	INJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for benztropine mesylate

Drug Class	Anticholinergic Antihistamine
Mechanism of Action	Cholinergic Antagonists Histamine Receptor Antagonists

Medical Subject Heading (MeSH) Categories for benztropine mesylate

Antiparkinson Agents

Dopamine Uptake Inhibitors

Muscarinic Antagonists

Parasympatholytics

US Patents and Regulatory Information for benztropine mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Usl Pharma	BENZTROPINE MESYLATE	benztropine mesylate	TABLET;ORAL	089213-001	Jun 14, 1988		DISCN	No	No
Lannett Co Inc	BENZTROPINE MESYLATE	benztropine mesylate	TABLET;ORAL	088895-001	Apr 11, 1985		DISCN	No	No
Merck	COGENTIN	benztropine mesylate	TABLET;ORAL	009193-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Invagen Pharms	BENZTROPINE MESYLATE	benztropine mesylate	TABLET;ORAL	090294-002	Mar 29, 2010		DISCN	No	No
Quantum Pharmics	BENZTROPINE MESYLATE	benztropine mesylate	TABLET;ORAL	088514-001	Jan 31, 1984		DISCN	No	No
Ph Health	BENZTROPINE MESYLATE	benztropine mesylate	TABLET;ORAL	040715-003	Aug 27, 2007	AA	RX	No	No

Market Dynamics and Financial Trajectory for Benztropine Mesylate

Last updated: February 19, 2026

Benztropine mesylate, a central nervous system agent primarily used for Parkinson’s disease and drug-induced extrapyramidal symptoms, exhibits limited market expansion relative to blockbuster drugs. Its economic profile is influenced by regulatory status, patent landscape, therapeutic niche, and competition.

Market Overview

The global CNS drug market was valued at approximately $50 billion in 2022, with anticholinergic agents comprising a smaller segment within movement disorder treatments. Benztropine mesylate is classified as off-patent in most regions, with no recent peak exclusivity, constraining high-margin potential.

Key Therapeutic Uses

• Parkinson's disease management
• Treatment of drug-induced extrapyramidal symptoms

These indications limit broad applicability, making the drug’s primary revenue drivers niche in nature rather than mass-market.

Regulatory and Patent Landscape

• No active patents for benztropine mesylate in major markets (US, EU, Japan)
• Generic versions available since the early 2000s
• Lacks recent regulatory exclusivity opportunities due to absence of new formulations or delivery methods

Market Participants and Competition

Major pharmaceutical companies producing generic benztropine mesylate include:

• Teva Pharmaceuticals
• Sandoz
• Sun Pharmaceutical Industries

Although the drug remains available, it faces competition from alternative therapies for Parkinson’s disease, including levodopa/carbidopa and dopamine agonists, which have broader usage profiles and ongoing R&D investments.

Competitive Landscape

• Limited pipeline development due to the drug's age and niche use
• No significant new formulations or delivery innovations announced recently

Financial Trajectory Projections

Revenue Analysis

• US sales estimated at $10–15 million annually, primarily from generic distributors
• Margins constrained by the presence of generic competition
• No recent data suggests a substantial growth trajectory

Cost and Pricing Dynamics

• Stable, low-cost manufacturing process
• Pricing driven downward by generic competition
• Limited pricing power due to off-patent status

Future Outlook

• No significant growth expected over the next five years without new indications or formulations
• Potential decline in market share driven by newer treatments with improved efficacy or safety profiles

Market Drivers and Risks

Drivers

• Ongoing need for symptomatic management in Parkinson’s disease
• Established safety and efficacy profile

Risks

• Shift toward newer therapeutic agents
• Regulatory and reimbursement pressures favoring innovative drugs
• Geographic variation impacting access and utilization

Summary

Benztropine mesylate’s market remains stable but limited by lack of patent protection, minimal innovation, and competition from advanced therapies. Financial prospects reflect modest steady revenues primarily derived from generics, with little potential for significant expansion absent new clinical developments.

---

Key Takeaways

• Market size is approximately $10–15 million annually in the US.
• The drug faces intense generic competition, pressuring prices and margins.
• No recent R&D or regulatory exclusivity efforts suggest limited growth.
• Competition from newer therapies constrains future revenue potential.
• The treatment uses are niche, impacting overall market dynamics.

FAQs

Q1: What is the patent status of benztropine mesylate?
A: It is off-patent in major markets, with generic versions available since the early 2000s.

Q2: Are there any new formulations or delivery methods in development?
A: No public indications exist there are ongoing research efforts or new formulations.

Q3: What are the main competitors for benztropine mesylate?
A: Other anticholinergic agents and newer Parkinson’s treatments such as levodopa/carbidopa.

Q4: Can the market for benztropine mesylate grow significantly?
A: No, limited by its niche indication, competition, and lack of recent innovations.

Q5: How does pricing impact the revenue?
A: Prices are driven downward by the presence of generics, limiting revenue growth.

---

References

1. Market data sourced from IQVIA, 2022.
2. Patent and regulatory landscape information from FDA and EMA databases, 2023.
3. Competitive market analysis from EvaluatePharma, 2023.